Related Experiment Video
Updated: May 19, 2026
09:57
In Vitro Assays to Evaluate the Migration, Invasion, and Proliferation of Immortalized Human First-trimester Trophoblast Cell Lines
Published on: March 5, 2019
Pravastatin does not prevent antiphospholipid antibody-mediated changes in human first trimester trophoblast function
Ebelechukwu A Odiari1, Melissa J Mulla, Anna K Sfakianaki
1Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06510, USA.
Human Reproduction (Oxford, England)
|August 14, 2012
Summary
Pravastatin did not prevent antiphospholipid antibody effects on human trophoblast cells. This study indicates pravastatin is not effective for preventing pregnancy complications in antiphospholipid syndrome.
Area of Science:
- Reproductive immunology
- Maternal-fetal medicine
- Pharmacology
Background:
- Antiphospholipid syndrome (APS) is linked to pregnancy complications like pre-eclampsia due to antiphospholipid antibodies (aPL) targeting the placenta.
- Current treatments like heparin reduce pregnancy loss but not severe pre-eclampsia, necessitating alternative therapies.
- Statins have shown promise in animal models, but their efficacy in human pregnancy models of APS is unstudied.
Purpose of the Study:
- To investigate the effect of pravastatin on antiphospholipid antibody (aPL) modulation of human first trimester trophoblast function.
- To assess whether pravastatin can mitigate aPL-induced adverse effects on trophoblast cells, relevant to managing APS in pregnancy.
Main Methods:
- Human first trimester trophoblast cell line (HTR8) and primary cultures were treated with a mouse anti-human β(2)GPI monoclonal antibody (aPL) with or without pravastatin.
- Cytokine and angiogenic factor secretion were quantified using ELISA and multiplex analysis.
- Trophoblast cell migration was assessed using a two-chamber migration assay.
Main Results:
- Pravastatin augmented aPL-dependent secretion of IL-8 and IL-1β, and soluble endoglin in HTR8 cells.
- Pravastatin did not affect aPL-induced changes in VEGF, PlGF, or GRO-α secretion.
- Pravastatin alone inhibited basal HTR8 cell migration and did not counteract aPL's negative impact on migration; similar results were observed in primary trophoblast cells.
Conclusions:
- Pravastatin does not prevent the detrimental effects of antiphospholipid antibodies on human first trimester trophoblast cell function in vitro.
- These findings suggest pravastatin may not be an effective treatment for preventing pregnancy complications in patients with APS.
- Further in vivo studies are needed to fully ascertain pravastatin's role in managing aPL-associated pregnancy complications.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...